Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200148 | 0.89 | MAPT (0.51) | KDM4EALDH1A1HSD17B10GAAMAPT | |
| SCHEMBL4186491 | 0.89 | CTSS (0.46) | KDM4EALDH1A1HSD17B10GAAKMT2A | |
| SCHEMBL4199612 | 0.89 | POLB (0.41) | KDM4EALDH1A1HSD17B10GAATAAR1 | |
| SCHEMBL4195525 | 0.88 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10MAPTLMNA | |
| SCHEMBL4202203 | 0.86 | KMT2A (0.49) | KDM4EALDH1A1HSD17B10GAAKMT2A | |
| SCHEMBL4192826 | 0.86 | MAPT (0.45) | KDM4EALDH1A1GAAMAPTLMNA | |
| SCHEMBL4197733 | 0.84 | ALDH1A1 (0.48) | ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4190300 | 0.84 | PKM (0.49) | KDM4EALDH1A1HSD17B10GAALMNA | |
| SCHEMBL4202147 | 0.83 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10GAALMNA | |
| SCHEMBL4192534 | 0.83 | TRPV1 (0.43) | KDM4EALDH1A1HSD17B10GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1432714-B1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2008-08-06 | — | — | EP | claimed |
| CN-101203504-A | Antimicrobial agents | RANBAXY LAB LTD (IN) | 2008-06-18 | — | — | CN | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| CN-101203504-B | Antimicrobial agents | RANBAXY LAB LTD | 2012-11-14 | — | — | CN | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
| CN-101203504-A | Antimicrobial agents | RANBAXY LAB LTD (IN) | 2008-06-18 | — | — | CN | disclosed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | KDM4E 3328/4885ALDH1A1 2744/4885HSD17B10 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.